Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers May 24, 2017
Pharmacy Choice - News - Pharmaceutical Development - May 24, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/24/17 - ABL Increases Aseptic Fill/Finish Capacity with State-of-the-Art, Fully Automated Vial Filling Line
By a News Reporter-Staff News Editor at Biotech Week ABL, Inc., a leading contract research, development and biomanufacturing organization to the biopharmaceutical industry worldwide, is proud to announce the successful expansion of its aseptic fill/finish operations at its Rockville, MD GMP biomanufacturing facility with the installation of a ne
5/24/17 - Agilis Biotherapeutics Announces Presentation of Data from Phase I/II Trial for Treatment of AADC Deficiency
The gene therapy treatment candidate, AGIL-AADC, is an adeno-associated virus vector containing the human gene for the AADC enzyme. Dr. Hwu stated, "We are pleased to present this important work highlighting the encouraging safety and efficacy observed to date in which AADC deficiency patients treated with the AGIL-AADC gene therapy have exhibited.
5/24/17 - ALUNBRIGTM brigatinib Approved for the Treatment of ALK+ Metastatic Non-Small Cell Lung Cancer, Available for Order at Biologics, Inc.
By a News Reporter-Staff News Editor at Biotech Week Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Takeda Pharmaceutical Company Limited, through its wholly-owned subsidiary ARIAD Pharmaceuticals, Inc., to be a specialty pharmacy provider as part of the distribution network for ALUNBRIGTM.
5/24/17 - Ammonett Pharma Receives Positive Opinion from European Orphan Medicinal Products Committee for MK-0677 for Treatment of Pediatric Growth Hormone Deficiency [Sudan Tribune]
-Ammonett Pharma LLC, a privately-held biotechnology company developing a novel, daily, orally-administered mini-pill Growth Hormone secretagogue, today announced that the European Medicines Agencys Committee for Orphan Medicinal Products issued a positive opinion recommending the Companys MK-0677 for designation as an orphan medicinal product...
5/24/17 - AZs Bydureon disappoints in diabetes outcomes trial [Sudan Tribune]
The FDA now obliges companies with diabetes products to conduct large scale cardiovascular outcomes trials, and the once weekly GLP-1 drug Bydureon was studied for its effects on a composite measure of major adverse CV events. Novo Nordisks rival GLP-1 treatment Victoza is close behind, and is expected to gain FDA approval for similar claims this y
5/24/17 - Biogen buys Remedy Pharmaceuticals` stroke drug Cirara [Syrian Arab News Agency]
Biogen last week completed an asset purchase of Remedy Pharmaceuticals phase 3 candidate, Cirara. The US Food and Drug Administration recently granted Cirara Orphan Drug Designation for severe cerebral edema in patients with acute ischemic stroke. Each year approximately 1.7 million ischemic strokes occur across the US, Europe and Japan, and...
5/24/17 - CANbridge Raises $25M Series B Financing [T-break Tech (Middle East)]
CANbridge Life Sciences, a Beijing, China- based clinical-stage biopharmaceutical company focused on developing Western drug candidates in China and North Asia, raised $25 m in Series B funding. Led by James Xue, PhD, Chairman and CEO, CANbridge is a clinical-stage bio-pharmaceutical company accelerating development and commercialization of special
5/24/17 - Caprion Biosciences Inc. will present at the 5th Annual Biopharmaceutical Emerging Best Practices Association BEBPA Conference highlighting the...
Caprion Biosciences Inc. will present at the 5th Annual Biopharmaceutical Emerging Best Practices Association BEBPA Conference highlighting the latest developments in Host Cell Protein HCP analysis. By a News Reporter-Staff News Editor at Biotech Week Caprion Biosciences Inc. a worldwide leading specialty CRO laboratory announced that Dr.
5/24/17 - Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial [Sudan Tribune]
-Cytori Therapeutics, Inc., today announced that it has now completed all 48 week follow up monitoring visits in its U.S. FDA approved Phase III STAR trial. A total of 88 subjects were enrolled and the last subjects 48 week visit was conducted earlier this week. In the United States, the scleroderma affected population appears to be approximately 1
5/24/17 - Debiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset From ImmunoGen
Transaction a dds i nnovative c linical- s tage p rogram to e xpanding Debiopharm p ortfolio and broadens its clinical development expertise. Debiopharm International SA, part of Debiopharm Group?, a Switzerland- based biopharmaceutical company, and ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of
5/24/17 - FDA Approves First Cancer Treatment for Any Solid Tumor with a Specific Genetic Feature
The U.S. Department of Health and Human Services' Food and Drug Administration issued the following news release:. "This is an important first for the cancer community," said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research and director of the FDA's Oncolog
5/24/17 - FDA approves Merck's bladder cancer drug
The FDA has approved two new indications for Merck's Keytruda (pembrolizumab), the company's anti-PD-1 therapy, for bladder cancer...
5/24/17 - FDA approves Roche's Actemra/RoActemra (tocilizumab) for giant cell arteritis
-Actemra/RoActemra is the first FDA- approved treatment for adults with giant cell arteritis. -FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra/RoActemra in GCA. "Today's FDA decision means people living with giant cell arteritis will, for the first time, have an FDA- approved treatment option for this debili
5/24/17 - ICON and Regeneron Win Best Partnership in Clinical Research Award from PharmaTimes
ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, and Regeneron Pharmaceuticals, Inc., a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions
5/24/17 - Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency at 2017 American Thoracic Society International Conference
Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today announced that a poster comprising updated data from the Company s U.S. Phase 2 clinical trial of its proprietary inhaled Alpha-1 Antitrypsin therapy for the treatment of Alpha-1 Antitrypsin Deficiency was presented by Professor Mark Brantly, M.D.,
5/24/17 - KCR Expands Its Presence in the U.S. Market
By a News Reporter-Staff News Editor at Biotech Week KCR, a full service contract research organization, has announced that it will be moving to a new office in Boston, MA, United States. The Boston area is a top pharma and biopharma hub with Massachusetts ranked the most innovative U.S. state by Bloomberg. "With our new Boston location, our US
5/24/17 - Merck Says FDA Approves New Indication For KEYTRUDA
WHITEHOUSE STATION- Merck said that the U.S. Food and Drug Administration has approved a new indication for KEYTRUDA, the company's anti-PD-1 therapy. KEYTRUDA is now indicated for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high or mismatch repair deficient. solid tumors that have...
5/24/17 - MRK's Keytruda Scores Another FDA Nod, NBIX Disappoints, SBPH Achieves It
WHITEHOUSE STATION- Today's Daily Dose brings you news about FDA approval of Merck's Keytruda for yet another indication; Neurocrine's disappointing phase II study of Ingrezza in Tourette syndrome; Spring Bank's results from phase 2 a segment of its ACHIEVE trial and Syndax' public offering. Achaogen Inc.' s lead product candidate Plazomicin, being
5/24/17 - NeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinsons Disease and Movement Disorders [Syrian Arab News Agency]
NeuroDerm Ltd., a clinical stage pharmaceutical company developing drug-device combinations for central nervous system disorders, today announced that complete data from trial 006 will be showcased in a late-breaking poster session at the 21st International Congress of Parkinsons Disease and Movement Disorders, taking place June 4-8, 2017 in...
5/24/17 - New Clinical Trials and Studies Findings from Copenhagen University Hospital Outlined [Bacille Calmette-Guerin (BCG) vaccination at birth and...
By a News Reporter-Staff News Editor at Vaccine Weekly New research on Clinical Research- Clinical Trials and Studies is the subject of a report. According to news reporting originating in Hvidovre, Denmark, by NewsRx journalists, research stated, "BCG vaccination has been associated with beneficial non-specific effects on child health.
5/24/17 - Oncolytics Biotech Inc. Announces FDA Fast Track Designation for REOLYSIN in Metastatic Breast Cancer
By a News Reporter-Staff News Editor at Biotech Week Oncolytics Biotech Inc. announced that the United States Food and Drug Administration has granted Fast Track designation for REOLYSIN , the Company's proprietary immuno-oncology viral agent, for the treatment of metastatic breast cancer. Matt Coffey, President and CEO of Oncolytics Biotech
5/24/17 - Pierre Fabre Pharmaceuticals Acquires Promising Assets from Igenica Biotherapeutics in the Field of Immuno-Oncology
*Pierre Fabre Pharmaceuticals will leverage its cutting-edge expertise in monoclonal antibodies and immuno-conjugates along with its capabilities in clinical development and translational medicine to bring these assets to development stage. CASTRES, France Pierre Fabre, the 2 nd largest French private Pharmaceutical group, today announced the..
5/24/17 - Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test [Sport360]
Roche announced approval of the VENTANA PD-L1 Assay by the US Food and Drug Administration as a complementary diagnostic3 to provide PD-L1 status for patients with locally advanced or metastatic urothelial carcinoma 4 who are being considered for treatment with the FDA- approved anti-PD-L1 immunotherapy IMFINZI. "We are very pleased the VENTANA PD
5/24/17 - Seattle Children's Brings First-of-its-kind Precision Medicine Clinical Trial to Inflammatory Bowel Disease, Bone Marrow Transplant Patients
Seattle Children's Hospital issued the following news release:. In an effort to find new strategies to personalize treatment for pediatric patients, Seattle Children's has opened the first clinical trial applying next-generation T-cell receptor sequencing and single-cell gene expression analysis to better understand how the immune system drives...
5/24/17 - SOM Biotech announces a worldwide license with Corino Therapeutics, Inc. for SOM0226, a drug for the treatment of TTR Amyloidosis.
SPAIN SOM Biotech Ltd a leading clinical-stage biopharmaceutical company specialized in drug repurposing to treat rare diseases with a focus on CNS diseases, today announces an exclusive worldwide license agreement with U.S. based Corino Therapeutics, Inc., for the clinical development and commercialization of SOM0226, a drug for the treatment of
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement